NKTR Nektar Corp: רווח נקי למניה ב-12 החודשים האחרונים

Nektar Therapeutics (NKTR) specializes in developing immunological drugs, relying on grants and clinical milestones. The annual EPS growth rate over the last 12 months reflects the business dynamics, where the value of 18.90 corresponds to the current metric. Share price growth depends on the success of rezpegaldesleukin and new alliances, while the company urgently restructures its innovation pipeline following a series of setbacks.
NKTR (Nektar Therapeutics Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Year-over-year EPS growth (TTM) measures the percentage change in trailing twelve-month earnings per share, enabling daily tracking of the market consensus without quarterly lags. Analyzing the historical annual dynamics of TTM EPS reveals how Nektar Therapeutics (NKTR) leverages production and research outsourcing to impact net efficiency, helping investors identify hidden financial vulnerabilities in a timely manner through the stability of the chart.